Skip to content
X-twitter Linkedin Youtube
  • FR
  • EN
  • FR
  • EN
  • HERV Approach
    • A novel approach
    • HERV in MS
    • HERV in Post-COVID
    • HERV in ALS
    • Other HERV-mediated diseases
    • Pipeline Overview
    • Intellectual Property
  • Post-COVID
    • HERV in Post-COVID
    • Clinical trial
    • Publications
  • Clinical Trials
  • News & Media
    • News & Press
    • Scientific publications
  • Investors
    • GNRO Shares
    • GeNeuro’s main shareholders
    • Analyst coverage
    • Stock price
    • Press releases
    • Annual reports / Registration documents
    • AMF Regulated information
    • Company governance
    • Financial events
    • Investor relations
  • About GeNeuro
    • Company Overview
    • Company History
    • The Board of GeNeuro
    • Management
    • General meetings
  • Contact
Menu
  • HERV Approach
    • A novel approach
    • HERV in MS
    • HERV in Post-COVID
    • HERV in ALS
    • Other HERV-mediated diseases
    • Pipeline Overview
    • Intellectual Property
  • Post-COVID
    • HERV in Post-COVID
    • Clinical trial
    • Publications
  • Clinical Trials
  • News & Media
    • News & Press
    • Scientific publications
  • Investors
    • GNRO Shares
    • GeNeuro’s main shareholders
    • Analyst coverage
    • Stock price
    • Press releases
    • Annual reports / Registration documents
    • AMF Regulated information
    • Company governance
    • Financial events
    • Investor relations
  • About GeNeuro
    • Company Overview
    • Company History
    • The Board of GeNeuro
    • Management
    • General meetings
  • Contact

Tag: 2018

Variation in proviral content among human genomes mediated by LTR recombination

Mobile DNA, December 18, 2018 https://geneuro.ch/data/news/2018-12-Mobile-DNA-Variation-in-proviral-content-among-human-genomes-mediated-by-LTR-recombination-Thomas-Perron-Feschotte.pdf

Rescuing the negative impact of human endogenous retrovirus envelope protein on oligodendroglial differentiation and myelination

Glia, November 14, 2018 https://geneuro.ch/data/news/2018-11-Go-ttle-et-al.-GLIA.pdf

GNbAC1 shows efficacy on MRI measures of neurodegeneration in relapsing-remitting MS patients over 48 weeks

Robert Glanzman at the 26th Annual Meeting of the European Charcot Foundation (November 2018) in Baveno, Italy https://www.pnas.org/content/116/30/15216

HERV-W-Env involvement in human T1D pathogenesis

S. Levet, J. Joanou, N. Queruel, J.Pierquin & H. Perron https://geneuro.ch/data/news/18-05-22-Poster-ADA-2018-V2.pdf

A new therapeutic approach for type 1 diabetes: Rationale for GNbAC1, an anti‐HERV‐W‐Env monoclonal antibody

Diabetes, Obesity and Metabolism, May 10, 2018 https://onlinelibrary.wiley.com/doi/10.1111/dom.13357

© 2025 GeNeuro SA

  • Legal Notice

 3, Chemin du Pré-Fleuri
CH-1228 Plan-les-Ouates
Geneva, Switzerland

  • contact@geneuro.com
X-twitter Linkedin Youtube